From injection therapies to natalizumab: Views on the treatment of multiple sclerosis

Roberto Bomprezzi, Darin Okuda, Yazan J. Alderazi, Olaf Stüve, Elliot Frohman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary.

Original languageEnglish (US)
Pages (from-to)97-104
Number of pages8
JournalTherapeutic Advances in Neurological Disorders
Volume5
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Multiple Sclerosis
Injections
JC Virus
Progressive Multifocal Leukoencephalopathy
Serology
Therapeutics
Costs and Cost Analysis
Natalizumab

Keywords

  • JC virus serology
  • multiple sclerosis
  • natalizumab
  • progressive multifocal leukoencephalopathy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pharmacology

Cite this

From injection therapies to natalizumab : Views on the treatment of multiple sclerosis. / Bomprezzi, Roberto; Okuda, Darin; Alderazi, Yazan J.; Stüve, Olaf; Frohman, Elliot.

In: Therapeutic Advances in Neurological Disorders, Vol. 5, No. 2, 03.2012, p. 97-104.

Research output: Contribution to journalArticle

@article{20918281202646d8b0ab3dcc4c7ec4f4,
title = "From injection therapies to natalizumab: Views on the treatment of multiple sclerosis",
abstract = "Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary.",
keywords = "JC virus serology, multiple sclerosis, natalizumab, progressive multifocal leukoencephalopathy",
author = "Roberto Bomprezzi and Darin Okuda and Alderazi, {Yazan J.} and Olaf St{\"u}ve and Elliot Frohman",
year = "2012",
month = "3",
doi = "10.1177/1756285611431289",
language = "English (US)",
volume = "5",
pages = "97--104",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - From injection therapies to natalizumab

T2 - Views on the treatment of multiple sclerosis

AU - Bomprezzi, Roberto

AU - Okuda, Darin

AU - Alderazi, Yazan J.

AU - Stüve, Olaf

AU - Frohman, Elliot

PY - 2012/3

Y1 - 2012/3

N2 - Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary.

AB - Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary.

KW - JC virus serology

KW - multiple sclerosis

KW - natalizumab

KW - progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=84858635267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858635267&partnerID=8YFLogxK

U2 - 10.1177/1756285611431289

DO - 10.1177/1756285611431289

M3 - Article

C2 - 22435074

AN - SCOPUS:84858635267

VL - 5

SP - 97

EP - 104

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

IS - 2

ER -